Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Core One Labs Inc (OP: CLABF ) 0.0877 -0.0100 (-10.24%) Streaming Delayed Price Updated: 3:01 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Core One Labs Inc < Previous 1 2 Next > Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market December 08, 2023 Via ACCESSWIRE Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods December 01, 2023 Via ACCESSWIRE Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease August 04, 2023 Via ACCESSWIRE Core One Labs' Scientists Successfully Complete Breakthrough First Step in Producing API-Grade DMT September 02, 2022 Via ACCESSWIRE Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass August 01, 2023 Via ACCESSWIRE Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease July 28, 2023 Via ACCESSWIRE Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More July 24, 2023 Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal... Via Benzinga Core One Labs Enters Into LOI For First Sale Of Its Psychedelic Compounds July 24, 2023 GMP Drug Inc., a wholly-owned subsidiary of Core One Labs Inc. (OTCQB: CLABF) (CSE:COOL)(Frankfurt:LD6) (WKN: A3CSSU) has entered into a non-binding letter of intent with Zollaris Laboratories... Via Benzinga Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin July 11, 2023 Via ACCESSWIRE Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method July 07, 2023 Via ACCESSWIRE Core One in Talks with Multiple Companies to Supply Psilocybin May 05, 2023 Via ACCESSWIRE Core One Labs' GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Psychedelic Prodrugs with Long-established Compounding Pharmacy May 01, 2023 Via ACCESSWIRE Core One's Awakened Lays The Groundwork For The Large-Scale Production Of Psychedelic Compounds With Synthetic Production Of Psilocin April 24, 2023 Core One Labs Inc. (OTCQB: CLABF) (CSE:COOL)(Frankfurt:LD6) (WKN:A3CSSU) announced that its wholly-owned subsidiary, Awakened Biosciences Inc. Via Benzinga Core One's Awakened Completes Successful Synthetic Production of Psilocin in its GMP Certified Manufacturing Facility April 21, 2023 Via ACCESSWIRE Across The Globe: Psychedelic Trials To Treat Late-Stage Cancer, Alzheimer's Begin January 26, 2023 Core One Labs' Akome Partners To Study Next-Gen Psychedelics Via Benzinga Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More January 25, 2023 Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? Via Benzinga Core One Labs' Akome Signs Contract with University of Barcelona: Initiating Animal Model Studies on Psychedelics Drug Development to Combat a Variety of Neurological Diseases January 24, 2023 Via ACCESSWIRE Here Are The Latest Psychedelics Partnerships From Production & Supply Chain To Community Action January 21, 2023 Let’s do a quick tour of some of the latest announcements made by psychedelics companies over the past week. We promise you’ll be informed in less time than it takes to brew your coffee. New,... Via Benzinga Core One Labs' Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and Other Drug Developers January 13, 2023 Via ACCESSWIRE Psyched: Canada's Psychedelic Therapy Guidelines, $39M Series B For Next-Gen Drugs, Mexico's Ancestral Roots & More December 28, 2022 Canada: Fed Guidelines For Psychedelic Therapy, Quebec Treatment Costs, Access And Magic Mushrooms Dispensaries Via Benzinga Psychedelic Mushrooms Soon To Be Commercially Produced And Sold In Canada December 21, 2022 After a successful commercial production trial, life sciences biotech company Core One Labs Inc. (OTCQB: CLABF) is set to begin commercial production of its clinical-grade psilocybin at a Good... Via Benzinga Core One Labs’ Prepares for Commercial Production of API-Grade Psilocybin; Plans Initial Production Run at GMP Facility in January November 18, 2022 Via ACCESSWIRE Core One Labs Takes Next Steps to Prepare for Potential Takeover Opportunities October 21, 2022 Via ACCESSWIRE European University to Fund Core One Labs' Akome Advanced Neurogenesis Stimulation Studies October 14, 2022 Via ACCESSWIRE Core One Labs Nearing GMP Production as Canada’s Province of Alberta Announces Game Changing Legislation October 07, 2022 Via ACCESSWIRE Core One Labs Announces Breakthrough with Proprietary Isolation and Purification Method of Psilocybin from Mushrooms; Prepares Patent Application September 30, 2022 Via ACCESSWIRE Psychedelics Developer & Mass-Scale Manufacturer Will Deliver Novel Magic Mushroom Products September 26, 2022 Life sciences biotech company Core One Labs Inc. (OTCQB: CLABF) signed a Letter of Intent with GMP-certified manufacturer Medelys Laboratories International Inc. for the manufacturing of its... Via Benzinga Core One Labs Signs Letter of Intent with GMP Manufacturing Partner for Production of Proprietary Psychedelic Compounds September 23, 2022 Via ACCESSWIRE Core One Labs' Akome Move Psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential September 16, 2022 Via ACCESSWIRE New Biosynthetic Psilocybin Hits The Psychedelics Market, Available For Research And Clinical Trials September 02, 2022 With psilocybin among the favorites within psychedelics, Via Benzinga < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
